Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of Tigulixostat (IBI128) in Healthy Chinese Subjects
NCT06277752Phase 1Completed
- Sponsor
- Innovent Biologics
- Start
- Mar 2024
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tigulixostat in gout and hyperuricemia (5 arms), sponsored by Innovent Biologics. Primary endpoints: Maximum Plasma Concentration, Area Under the Curve and 2 more. Started Mar 2024; status: completed.
02
Drugs
tigulixostat
03
Conditions
gouthyperuricemia
Beyond the preview
Go deeper on NCT06277752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06277752.